Navigation Links
Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
Date:9/5/2007

U.S. Biogeneric Agents to Reach $2 Billion in Sales by 2016, According to a

New Report from Decision Resources

WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen, the leading manufacturer of biologic agents with biologic sales of more than $14 billion in 2006, and Genentech, the second leading biologics manufacturer with biologic sales of more than $9 billion in 2006, are bracing themselves for heavy pressure from biogeneric manufacturers. According to the new special report entitled Biogenerics 2007- 2016: Physician and Payer Acceptance Fuels Brand Erosion, Amgen products such as Enbrel, Epogen and Neupogen will be eroded by biogeneric sales in both the United States and Europe. In fact, on August 31, 2007, European regulators approved Sandoz's biogeneric epoetin alfa for patients with renal anemia and those receiving chemotherapy. Genentech products such as Rituxan/MabThera and Herceptin represent windfall opportunities for biogeneric hopefuls.

The report also reveals that, with the launch of biogeneric TNF-alpha inhibitors in 2012, the U.S. biogeneric market will expand substantially through 2016 and reach a total of more than $2 billion in annual sales.

"This growth in the U.S. biogeneric market will be driven by biogeneric TNF-alpha inhibitors for rheumatoid arthritis, which we project will generate $700 million in sales by 2016, and will be supported by biogeneric versions of interferon-betas for multiple sclerosis, Herceptin for breast cancer, and ESPs for chemotherapy-induced anemia, each of which will post more than $250 million in 2016 U.S. sales," said Andrew Merseth, analyst at Decision Resources.

About Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion

Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion covers 13 key biologic brands used in eight indications and includes more primary research than any other report produced by Decision Resources. It includes surveys of 317 specialists from the United States, France, and Germany as well as 40 U.S. HMO pharmacy directors. The report includes a 10- year annualized forecast for the 13 key brands and for their biogeneric competition, and provides a framework for forecasting other biogenerics.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Genentechs Winning Streak
2. TeraMedica embraces open source project
3. Center for Technology Transfer embraces "Cleantech"
4. Wisconsin Film Festival embraces new online ticket ordering system
5. Wisconsin Historical Society Embraces New Web Site Technology
6. Chippewa Valley Embraces Nanotechnology
7. Wisconsin early-stage companies must position themselves to get capital
8. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
9. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
10. Cellular Dynamics hits market with UW research heavyweights
11. Governors Growth Council hopes to go light on paperwork and heavy on ideas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):